Introduction
Anti-M€ ullerian hormone (AMH) is a member of the transforming growth factor-b superfamily secreted exclusively by the gonads. In males, AMH promotes regression of M€ ullerian ducts in utero, while in females it regulates recruitment of primordial ovarian follicles and is a sensitive marker of ovarian reserve. 1 Minimal fluctuations in AMH concentration within the menstrual cycle makes AMH a more reliable biomarker than most other ovarian hormones. 2 The protective effect of AMH against development of tumors of the female reproductive tract was first hypothesized in the early 1980s. 3 The M€ ullerian ducts of female fetuses evolve into the fallopian tubes, endometrium, and endocervix. Ovarian "surface epithelial" neoplasms are hypothesized in most cases to arise from M€ ullerian epithelium (e.g., fallopian tube, endometrium) or ovarian surface mesothelium that has undergone M€ ullerian transformation. 4 Based on the inhibitory role of AMH on the M€ ullerian ducts during sexual differentiation, AMH was speculated to inhibit ovarian cancer development. In vitro and animal studies subsequently demonstrated that AMH decreases ovarian cell proliferation rates, tumor growth, and steroid synthesis, while What's new? As the anti-M€ ullerian hormone (AMH) inhibits M€ ullerian duct formation during sexual differentiation, an inhibitory role of the AMH in ovarian cancer development was proposed. Here the authors performed a pooled analysis of nine cohorts of mostly late premenopausal women testing a potential protective role of AMH against ovarian carcinogenesis. Contrary to animal and experimental studies, the authors found no associations between AMH and ovarian cancer risk, pointing to future studies in younger women with overall higher AMH concentrations to conclusively establish whether AMH reduces ovarian cancer risk.
increasing apoptosis in ovarian cancer cell lines, although at supra-physiologic levels. [5] [6] [7] [8] [9] Mechanistic studies have also shown that AMH binds to AMH receptors that are expressed in the ovaries [10] [11] [12] and, in turn, initiates a series of intracellular cascades that alter cell cycle regulating proteins and levels of transcription factors involved in cell proliferation and differentiation. [13] [14] [15] [16] However, there is sparse evidence in human populations for an association between circulating AMH concentration and subsequent risk of ovarian cancer. To date, the association has been evaluated in only one small nested case-control study of pregnant women and that study reported no overall association between AMH concentration and ovarian cancer risk. 17 Using a sensitive AMH assay, 18, 19 we examined the association between prediagnostic circulating levels of AMH in premenopausal women and the subsequent risk of ovarian cancer in nine cohorts.
Methods

Study population
Participants derive from the nine cohorts within the Prospective Study of AMH and Gynecologic Cancer Risk; the participating cohorts were the Columbia, Missouri Serum Bank (USA), 20 the Campaign Against Cancer and Heart Disease (CLUE I/II; USA), 21 the European Prospective Investigation into Cancer and Nutrition (EPIC; Europe), 22 the Guernsey Cohort Study (UK), 23 the New York University Women's Health Study (NYUWHS; USA), 24 the Nurses' Health Study and Nurses' Health Study II (NHS/NHSII;USA), 25 the Hormones and Diet in the Etiology of Breast Cancer (ORDET; Italy), 26 the Northern Sweden Health and Disease Study (NSHDS; Sweden), 27 and the Shanghai Women's Health Study (SWHS; China). 28 All participants provided informed consent. The current study was approved by the institutional review boards of each of the collaborating institutions and the University of Maryland, Baltimore.
Case-control selection
This analysis included premenopausal women aged <47 years with no history of cancer (other than non-melanoma skin cancer) at blood draw. This age cut-off was implemented because of the high frequency of AMH values below the assay limit of detection after 47 years of age in our earlier study of breast cancer. 20 Incident cases of ovarian cancer were ascertained through self-report and medical record review, 25 linkage to cancer registries, [21] [22] [23] [26] [27] [28] death registries 20, 23, 24 or all three methods. 20, 24 Information on tumor characteristics, including histology, stage and grade, were obtained through cancer registries, 20, 21, 24, 27 pathology reports, [22] [23] [24] and medical records. 25, 26, 28 Histology and grade were used to classify tumors as type I or type II. 29, 30 Type II tumors were defined as "high grade serous" or "serous, not otherwise specified (NOS)" (ICD-O-2 codes: 8461, 8441, 8450, 8460) with grade 2; for Shanghai Women's Health Study (for which grade data were not available), type II tumors were defined as "high grade serous" or "serous, NOS" with documentation of death from ovarian cancer. All other tumors (8310, 8323, 8380, 8442, 8451, 8462, 9014, 8470, 8741, 8480, 8481, 8472, 8473, 8640, 8800, 8950, 8951, 8980), except "carcinomas, NOS" and "sarcomas", which were set to missing for type I/II tumor categorization, were defined as type I tumors.
Eligible controls were premenopausal women <47 years old at blood draw who had no history of cancer other than non-melanoma skin cancer. One or two controls from NSHDS and one control from all other cohorts were matched per case by age at blood draw (88% were matched within 61 years; max 2.4 years) and date of blood draw (61 year), and other study-specific matching factors [20] [21] [22] [23] [24] [25] [26] [27] [28] (Supporting Information Table 1 ). Of the 304 cases and 339 matched controls initially identified, two cases of granulosa cell tumors and their matched controls (N 5 3) were excluded because of the well-known positive association of AMH with these tumors. 31 The final sample included 302 cases and 336 controls.
Measurement of circulating AMH
Each cohort selected plasma 21, 22, [25] [26] [27] [28] or serum samples [20] [21] [22] [23] [24] from eligible women, which were labeled to be indistinguishable as to case-control status. Samples were sent to a single location where they were organized into study-specific batches before being shipped to the Massachusetts General Hospital Clinical Laboratory Research Core (Boston, MA) for assay. Case-control sets were randomly ordered within cohort and assayed together using a picoAMH enzyme-linked immunosorbent assay kit (Ansh Catalog no. AL-124, Webster, TX). The coefficient of variation of the AMH assay, estimated from 61 blinded quality control replicates from a common pool of control samples, was 15.5%. The assay limit of detection was 20 pg/mL and <5% (N 5 29) had values below the assay limit of detection.
Demographic and lifestyle data
Cohorts collected participants' data on demographics, lifestyle, reproductive and menstrual histories, and medical history before or at the time of blood collection by self-report [20] [21] [22] [24] [25] [26] 32 and/ or interview. 23, 28 For the present analysis, data were available for age at blood draw, race, education, height, weight, body mass index (BMI), smoking status, age at menarche, total number of pregnancies, and oral contraceptive use.
Statistical analyses
Primary data obtained from the nine cohorts were harmonized to be uniformly defined and categorized. AMH values (N 5 2) measured in citrate plasma were converted to the corresponding AMH serum values using an equation provided by Ansh Labs to correct for dilution by citrate (personal communication with Ansh Labs). AMH concentration was categorized in study-specific quartiles based on the distribution in the controls; secondary analyses were also conducted using (i) study-wide common quartiles of AMH concentration, and (ii) common quartiles of cohort-adjusted AMH concentration, using the method of Rosner. 33 Studyspecific deciles of AMH, based on the distribution in the controls in each cohort, were also used to compare women with extreme AMH levels in relation to ovarian cancer risk.
The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression models. Tests for trend were conducted using the Wald statistic of the ordinal value of AMH quartiles. The following factors were initially considered as potential confounding factors in the multivariable model: BMI, ever use of oral contraceptives, total number of pregnancies, age at menarche, smoking status, education, and race. Missing values, for which there was a high proportion for some variables (Table 1) , were handled in one of two ways. Missing values for BMI, ever use of oral contraceptives, total number of pregnancies, age at menarche and smoking status were imputed 34 using a prediction model to create ten multiply imputed datasets, which included the imputed variables, age at blood collection, cohort, current oral contraceptive use, race, and education as predictors based on their distributions within each cohort. Otherwise, we used missing indicators for variables that were not collected in some cohorts (i.e., education in the Columbia and Guernsey cohorts; race in EPIC).
Of the potential confounding factors studied, age at menarche and oral contraceptive use were found to be associated with AMH and were retained in the final multivariable model. Age at blood draw (continuous) was also included in the final model, because of its strong inverse association with AMH. We obtained final pooled results by averaging results of analysis from each of the ten multiply imputed datasets using Rubin's rule. 35 The between-study heterogeneity of the pooled risk estimates from ten multiply imputed datasets was tested using the Q statistic assuming random effects. 36 Separate conditional logistic models were fit to evaluate associations of AMH with risk for ovarian tumor subtypes defined by tumor development pathway (Type I vs. , and by age at ovarian cancer diagnosis (<50 years vs. 50 years) and time between blood collection and diagnosis (5 years, >5 to <10 years, 10 years). The heterogeneity of the observed associations across subgroups was tested using a contrast test, 37 comparing the risk estimates of the ordinal trend terms from the conditional logistic regression models.
In subgroup analyses stratified by age at blood draw (<40 years vs. 40 years) and oral contraceptive use (never vs. ever), unconditional logistic regression models were used to preserve the number of subjects included in analyses. Models were fit using robust variances that adjusted for withincohort correlation, 38 while additionally adjusting for the matching factors common to all cohorts (age and year of blood collection). Interaction with AMH concentration was tested using the cross-product term between stratifying factor and AMH concentration. Inferences from unconditional logistic models did not differ from conditional models.
We also conducted several sensitivity analyses. To evaluate the potential effect of subclinical ovarian cancer on AMH concentration, we excluded cases diagnosed within one year of the date of blood draw (N cases 5 10). We also excluded women who were current users of oral contraceptives (N cases 57; N controls 5 12), and separately, those from one cohort (Guernsey) that stored blood at 2208 C (N cases 516; N controls 5 16).
All analyses were conducted using STATA version 13.0 (College Station, TX) or SAS version 9.4 (SAS Institute, Cary, NC). All tests were two-sided and considered significant if p values <0.05. Table 1 shows the population characteristics of the 302 cases and 336 controls included in this analysis. The majority of cases and controls were White. The mean age at blood draw was 40.6 years (range: 25.4-46.0 years) for the cases and 40.5 years (range: 24.1-46.8 years) for the controls. Compared to the controls, cases had a higher BMI, slightly earlier age at menarche, were less likely to be current or ever users of oral contraceptives, and were more likely to be never smokers. The median (interquartile range) AMH concentration was 1,035 pg/mL (300-2,230 pg/mL) in the cases and 1,025 pg/ mL (330-2,235 pg/mL) in the controls. The median age at diagnosis for the cases was 50.5 years, and the median time from blood draw to ovarian cancer diagnosis was 9.2 years ( Table 2 ). Ninety percent of ovarian cancer cases had data on histology; 51% had data on grade, and 70% had data on stage; of characterized tumors, 49% were serous, 55% were poorly differentiated (grade 3), and 65% had spread beyond the ovaries (stage 2). Cohort-specific participant characteristics are summarized in Supporting Information Table 2 . Age-adjusted median AMH concentration in controls ranged from 530 pg/mL in SWHS to 1,605 pg/mL in CLUE I/II, while mean age at blood draw ranged from 38.3 years in CLUE I/II to 43.1 years in SWHS.
Results
We observed no significant association between prediagnostic concentrations of AMH and the overall risk of ovarian cancer in either simple-or multivariable-adjusted models (OR Q4vsQ1 [95% CIs]: 0.99 [0.59-1.67], P trend : 0.91, P heterogeneity across studies : 0.48; Table 3 ). Additional adjustments for BMI, smoking status, race, total number of pregnancies, and education did not change results. Exclusion of ovarian cancer cases diagnosed within 1 year of blood collection, current users of oral contraceptives or samples from one cohort that were stored at 2208C, in separate sensitivity analyses, did not substantially alter the results (data not shown). The associations were similar when using common study-wide AMH quartiles or common quartiles of cohort-adjusted AMH (Supporting Information Table 3 ). Results also were similar when comparing more extreme AMH concentrations using deciles (Supporting Information Figure 1 ). Repeating analyses using missing indicators for all covariates instead of imputed values for some yielded similar non-significant associations (data not shown).
The non-significant associations of AMH concentration with the risk of overall ovarian cancer did not vary significantly according to age at blood draw (OR Q4vsQ1 We also examined associations with ovarian cancer defined by tumor characteristics and by age at and time to diagnosis (Table 5) . AMH concentrations were not 
Discussion
In this prospective analysis including nine cohorts, prediagnostic circulating concentration of AMH was not associated with overall ovarian cancer risk and did not differ by oral contraceptive use or age at blood draw. There also was no association with risk by specific ovarian tumor subtypes defined by Type I/II classification, stage, grade, age at diagnosis or time from blood draw to diagnosis. To date, only one prior nested case-control study (the Finnish Maternity Cohort, with 107 cases), not included in the current pooled analyses, 17 examined the association between AMH and risk of ovarian cancer. That study reported that AMH concentration in blood collected during the first trimester of pregnancy from women in their early thirties was not associated with subsequent risk of overall ovarian cancer (OR T3vs T1 : 0.93, 95% CIs: 0.49-1.77, P trend : 0.83). This result is consistent with our findings in older non-pregnant premenopausal women.
In contrast, these epidemiological findings are not consistent with results from animal and in vitro studies, which suggest that AMH suppresses the growth of ovarian tumors. [5] [6] [7] [8] [9] [14] [15] [16] While experimental studies have the advantage of being better able to control the exposure as well as potential confounding factors, their wider applicability to humans is not always clear, particularly when supraphysiologic concentrations of AMH are used. [5] [6] [7] [8] [9] [14] [15] [16] Additionally, even physiologic concentrations of AMH observed to regress the M€ ullerian ducts during the sexual differentiation, 39 are much higher than circulating concentrations in premenopausal women under normal circumstances. 6, 14 To our knowledge, our study is the first to evaluate associations of prediagnostic AMH concentration measured in blood Abbreviations: AMH, anti-M€ ullerian hormone; MV, multivariable. 1 Study-specific quartiles of AMH concentration, defined among controls, were used. 2 Test for trend was conducted using the Wald statistic of the ordinal value of study-specific quartiles of AMH concentration, modeled as a continuous term. 3 Conditional logistic regression model was conditioned on case/control matching factors and adjusted for age at blood draw (continuous, years). 4 Conditional logistic regression model was conditioned on case/control matching factors and adjusted for age at blood draw (continuous, years), oral contraceptive use (never, ever) and age at menarche (11 to <12 years, 12 to <13 years, 13 to <14 years, 14 years). 5 Heterogeneity across cohorts was not significant (P heterogeneity across studies 5 0.48). 
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collected from non-pregnant women with risk of subsequent ovarian cancer. The prospective design minimized potential for reverse causality as well as potential for biased recall of confounding factors. All AMH assays were performed in a single laboratory blinded to case-control status and using a new ultrasensitive AMH assay that is valid and reproducible. 18, 19 The primary data obtained at multiple sites was uniformly harmonized, standardizing covariate categorization for the statistical analysis.
A limitation of our study is that AMH was measured in a single blood sample collected during late menopause and may not reflect long-term concentrations or the relevant etiologic period. However, AMH concentrations track over time; the intra-class correlation of AMH over 1 year period in late premenopausal women was 0.87 in a previous study, 40 suggesting that misclassification of AMH concentration due to temporal variation in our study is likely to be small. Furthermore, circulating AMH concentrations could be less relevant for ovarian carcinogenesis, compared to intra-ovarian levels. Nonetheless, AMH is known to bind to AMH receptors expressed in the ovaries [10] [11] [12] to stimulate AMH signaling pathways. 41, 42 Despite the inclusion of nine cohorts from North America, Europe and China, we had limited power to examine associations of AMH with specific subtypes of ovarian cancer (Table 5) or to detect differences in stratified analysis. While we cannot rule out residual or unmeasured confounding, the similarity of the simple and multivariable models, suggest this is unlikely to be a major limitation.
In conclusion, in this analysis of nine cohorts of late premenopausal women, prediagnostic concentrations of AMH Abbreviations: AMH, anti-M€ ullerian hormone; MV, multivariable. 1 Study-specific quartiles of AMH concentration, defined among controls, were used. 2 Test for trend was conducted using the Wald statistic of the ordinal value of study-specific quartiles of AMH concentration, modeled as a continuous term. 3 Test for heterogeneity by type of cancer was conducted using the contrast test, comparing the risk estimates of the quartile ordinal trend term observed with each specific cancer type. 4 Cancer is defined as type II if cases were documented as high grade serous or serous, nos with grade 2 (for Shanghai Women's Health Study, because grade information was not available, high grade serous tumor was defined as cases documented as high grade serous or serous, nos and died of ovarian cancer), otherwise all other tumors, except those documented as carcinoma, nos and sarcoma, were defined as type I. 5 Conditional logistic regression model was conditioned on case/control matching factors and adjusted for age at blood draw (continuous, years), year of blood draw (quintiles, years), oral contraceptive use (never, ever), and age at menarche (11 to <12 years, 12 to <13 years, 13 to <14 years, 14 years). 6 Cancer is defined as early stage if stage at diagnosis is equal to 1, otherwise defined as late stage cancer. 7 Cancer is defined as low grade if grade at diagnosis is equal to 1, otherwise defined as high grade cancer.
were not associated with risk of overall ovarian cancer or its specific subtypes. Large epidemiologic studies of younger premenopausal women, where AMH concentrations are higher, are warranted to confirm the etiologic relevance of AMH in relation to ovarian carcinogenesis.
